Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T10:25:40.379Z.
Consensus retrieved: 2026-10-06T09:18:29.961Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T10:25:40.379Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 58a2fa14633c50703c8ff5f7fcb702de1515a66dae0cc773e6a723eda01f3aaa
Forward PE Ratio (N/A) = Dated Quote Price ($66.14) / Consensus Forward EPS ($-2.79)
FORWARD PE RATIO
N/A
BridgeBio Pharma, Inc.
Market Cap
$12.95B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | $12.95B | N/A |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 15.90 |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | N/A |
| Baxter International Inc. (BAX)vs › | $12.52B | 11.79 |
| Penumbra, Inc. (PEN)vs › | $12.49B | 67.36 |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.17B | 34.10 |
| Encompass Health Corporation (EHC)vs › | $12.00B | 19.79 |
| Ascendis Pharma A/S (ASND)vs › | $14.16B | N/A |
| DaVita Inc. (DVA)vs › | $11.47B | 12.10 |
| Bio-Techne Corporation (TECH)vs › | $11.36B | 35.48 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $66.14, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.79 | $-3.54 – $-1.98 | 12 | n/m |
| 2027-12-31 | $0.06 | $-0.26 – $0.33 | 12 | 1026.6x |
| 2028-12-31 | $3.88 | $0.60 – $7.75 | 14 | 17.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
